超短期强化他汀治疗对不稳定型心绞痛患者PCI术中无复流现象及血清hs-CRP的影响被引量：15

在线阅读下载PDF

导出

摘要目的探讨术前超短期强化阿托伐他汀治疗对不稳定型心绞痛患者经皮冠状动脉介入治疗(PCI)中无复流发生率及其血清高敏C反应蛋白(hs-CRP)的影响。方法选取行PCI的不稳定型心绞痛患者80例,随机分为强化他汀组及常规他汀组,强化他汀组在术前1 d给予阿托伐他汀80 mg,术后给予阿托伐他汀20 mg/d。常规他汀组术前1 d给予阿托伐他汀20 mg/d,术后给予阿托伐他汀20 mg/d。观察术中无复流现象发生率;分别检测术前及术后1周两组血清hs-CRP、低密度脂蛋白胆固醇(LDL-C)水平。结果强化他汀组术中发生无复流现象2例,常规他汀组发生无复流现象6例,两组比较,P<0.05;术后1周时两组LDL-C、hs-CRP水平均降低,强化他汀组hs-CRP水平较常规他汀组明显下降(P<0.05),但LDL-C水平差异无统计学意义(P>0.05)。结论术前超短期强化他汀治疗能减少不稳定型心绞痛患者PCI术中无复流的发生,降低患者血清hs-CRP水平。

作者吴春风胡柯

机构地区湘潭市中心医院中南大学湘雅三医院

出处《山东医药》 CAS 北大核心 2016年第17期71-72,共2页 Shandong Medical Journal

关键词不稳定型心绞痛阿托伐他汀经皮冠状动脉介入治疗无复流

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1杨树森,甘润韬,孙延明,王政,董国,潘薇.阿托伐他汀对ST段抬高型急性心肌梗死患者急诊PCI术后无复流现象的影响[J].临床心血管病杂志,2011,27(1):35-38. 被引量：41
2任美欣,严松彪,陈晖.直接经皮冠状动脉介入治疗前即刻应用大剂量阿托伐他汀对心肌再灌注损伤和心功能的影响[J].中国介入心脏病学杂志,2012,20(6):317-320. 被引量：13
3LI Xiang-dong YANG Yue-jin HAO Yong-chen YANG Ying ZHAO Jing-lin DOU Ke-fei GU Dong-feng.Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention： a meta analysis[J].Chinese Medical Journal,2013(9):1755-1760. 被引量：36
4丁汉元.PCI术前不同剂量阿托伐他汀强化治疗对UPA患者血清MCP-1、hs-CRP、sFas水平的影响[J].山东医药,2010,50(18):38-39. 被引量：3
5刘巧丽,张克成,王广友,李呼伦,袁杰.阿托伐他汀对大鼠急性心肌缺血再灌注无复流现象的影响及其机制[J].中国心血管杂志,2011,16(3):214-217. 被引量：10

二级参考文献36

1胡大一.2004年美国心脏协会年会热点简报[J].中华心血管病杂志,2005,33(2):189-192. 被引量：16
2Lim SY,Jeong MH,Bae EH.Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention[J].Circ J,2005,69(2):154-158.
3Newman CB,Palmer G,Silbershatz H,et al.Safety of atorvastatin derived from analysis of 4 completed trials in 9416 patients[J].Am J Cardiol,2003,92(6):670-676.
4Boyle JJ,Bowyer DE,Weissberg PL,et al.Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions[J].Arterioscler Thromb Vasc Biol,2001,21(9):1402-1407.
5Nissen SE,Tuzcu EM,Schoenhagen P,et al.Stafin therapy,LDL cholesterol,C-reactive protein,and coronary artery disease[J].N EnMed,2005,352(1):29.
6Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARM YDA-ACS randomized trial[J].J Am Coll Cardiol,2007,49(12):1272-1278.
7Erl W.Statin-induced vascular smooth muscle cell apoptosis:a possible role in the prevention of restenosis[J].Curr Drug Targets Cardiovasc Haematol Disord,2005,5(2):135-144.
8KIERNAN T J, RUGGIERO N J, BERNAL J M, et al. The no-reflow phenomenon in the coronary cireulation[J]. Cardiovasc Hematol Agents Med Chem,2009,7:181 -192.
9BROSH D, ASSALI A R, MAGER A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six- month mortality[J]. Am J Cardiol, 2007,99:442 - 445.
10VRINTS C J. Pathophysiology of the no-reflow phenomenon[J]. Acute Card Care, 2009,11 : 69- 76.